Clinical Trials Logo

Precancerous Conditions clinical trials

View clinical trials related to Precancerous Conditions.

Filter by:

NCT ID: NCT03830710 Completed - Premalignant Lesion Clinical Trials

8-Hydroxy-2-Deoxyguanosine ,Total Antioxidant Capacity in Oral Premalignant and Malignant Lesions

Start date: April 1, 2018
Phase:
Study type: Observational

Objectives: Investigating the level of salivary 8-hydroxy-2-deoxyguanosine (8-OHdG) and total antioxidant capacity (TAC) in oral premalignant and malignant lesions in order to determine their diagnostic value for the malignant patients. Design: 120 subjects diagnosed with oral leukoplakia, oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC) along with healthy control subjects were included. Salivary samples from all participants were collected. 8-OHdG was measured by ELISA technique and the TAC level was assessed by a photometric test system.

NCT ID: NCT03781661 Completed - Chest Pain Clinical Trials

Providing Patient Information and CT Examination Results

INFOCT
Start date: June 11, 2018
Phase: N/A
Study type: Interventional

Chest pain is a common cause of visits in the Emergency Room and General Practice, and is most commonly connected as a symptom of coronary disease, as for instance angina pectoris and acute myocardial infarct. Approximately 75-80% of these patients are not diagnosed with coronary disease or other cardiac findings. However, many of these patients still report chest pain and worries about cardiac disease. This study is based on patients that are referred to a CT-examination of the coronary arteries on the background of chest pain, where the CT-examination shows normal coronary arteries. The study aims to evaluate whether providing an intervention to this group of patients has an effect on patient satisfaction, patient's worry of cardiac disease and incidence of chest pain. The intervention group will be compared with a similar group going through the same CT-examination, but is receiving the examination result from their regular general practitioner (RGP), which is considered standard care. The hypothesis is that patients with chest pain with no coronary findings receiving extended information before getting the normal examination results experience a better patient satisfaction than those receiving the examination result from their RGP.

NCT ID: NCT03682562 Completed - Oral Cancer Clinical Trials

Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions

Start date: September 15, 2019
Phase:
Study type: Observational

This study aims to identify the accuracy of DNA integrity index in differentiating between oral premalignant lesions and oral cancer.

NCT ID: NCT03578965 Completed - Clinical trials for Premalignant Vulvar Lesion

Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions

Start date: July 13, 2018
Phase: Phase 2
Study type: Interventional

A randomized control trial will provide the most reliable data to determine the role of prophylactic antibiotics to decrease the wound complication rate. The investigators plan to perform a pilot study to evaluate actual rates of wound complications and how long it takes to recruit 50 patients.

NCT ID: NCT03268993 Completed - Clinical trials for Head and Neck Cancer

Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer

Start date: July 27, 2018
Phase: N/A
Study type: Interventional

Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication. In this study, participants who have been curatively treatment for head and neck cancer, will take Avmacol twice a day for 3 months.

NCT ID: NCT03208790 Completed - Premalignant Lesion Clinical Trials

Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

Start date: September 30, 2017
Phase: Phase 2
Study type: Interventional

The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B: Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)

NCT ID: NCT03100045 Completed - Clinical trials for Human Papilloma Virus

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

ART-AIN
Start date: April 20, 2017
Phase: Phase 1
Study type: Interventional

This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.

NCT ID: NCT03031899 Completed - Oral Lichen Planus Clinical Trials

Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy

Start date: March 2015
Phase:
Study type: Observational

Abstract Objective: To study the diagnostic efficiency of Rose Bengal with Toluidine blue in detecting the biopsy sites and thus establish an accurate diagnosis in oral premalignant lesions. Materials and method: In our study 27 patients with 41 lesions were included. Since one patient had not quit the habit in the two weeks following initial examination and another lesion disappeared in the waiting period, 2 patients (3 lesions) were not included in the study. Out of 38 lesions diagnosed based on clinical criteria, 32 were leukoplakia, 5 lichen planus and 1 SCC. After initial examination they were subjected to Rose Bengal and Toluidine blue stain. If stained positive they were subjected to biopsy.

NCT ID: NCT02821494 Completed - Clinical trials for Tumors or Premalignant Lesions

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Start date: March 2015
Phase: Phase 1
Study type: Interventional

A phase I study to establish the highest safe dose that induces HPV16 E6-specific T-cell responses, using the highly promising novel therapeutic vaccine concept named: Hespecta (HPV E Six Peptide Conjugated To Amplivant®) to induce HPV16 E6-specific T-cell responses.

NCT ID: NCT02323672 Completed - Oral Cancer Clinical Trials

Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions

Start date: February 2014
Phase: N/A
Study type: Observational

45 individuals were subdivided into 3 groups, 15 patients with oral premalignant lesions, 15 patients with oral malignant lesions and 15 control individuals. Levels of chemerin and MMP-9 were evaluated in serum and saliva of these subjects utilizing the ELISA technique.